Isomark Health raised its seed funds for identifying infections in 30 seconds using patented technology by UW-Madison scientists. Isomark’s Canarytm device fills a unique niche in the market with our novel real-time, pre-symptomatic diagnostic device. With no real competitors that can match Canarytm‘s sensitivity and general ability to detect and differentiate disease types, Canarytm device is truly a one-of-a-kind product.
The company recently received funding from Innova Memphis, Johnsonville Ventures, Bright Star, and additional Wisconsin investors. It is thanks to this funding that we have been able to develop the next generation of Canary device. Additionally, part of the funding will go towards a robust data pipeline that can work with any partner farms.